Results 91 to 100 of about 4,121 (173)

Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritis. [PDF]

Front Pharmacol
Ramonda R, Lorenzin M, Carletto A, Chimenti MS, Manara M, Cozzi G, Zabotti A, Foti R, Carriero A, Hoxha A, Selmi C, Raffeiner B, Giollo A, Cauli A, Salvarani C, Atzeni F, Rossini M, Fassio A, Nava F, Paci V, Moroncini G, Buonanno S, Frediani B, Luchetti Gentiloni MM, Gentileschi S.   +24 more
europepmc   +1 more source

Fibrinogen-to-Platelet Ratio and Hematologic Inflammatory Indexes in Spondylarthritis. [PDF]

J Clin Med
Ungureanu RD, Bita CE, Voicu MN, Turcu-Stiolica A, Firulescu SC, Turcu-Stiolica M, Bărbulescu AL, Dinescu SC, Vreju FA.   +8 more
europepmc   +1 more source

Clinical evidence and implementation guidance for biosimilar switching in ankylosing spondylitis. [PDF]

Front Pharmacol
Cai L, Chen X, Fang Y, Li L, Liu T, Gan Z, Zuo Z.   +6 more
europepmc   +1 more source

Fatigue in Middle-Aged and Older Adults with Axial Spondyloarthritis: A Sex-Stratified Case-Control Study. [PDF]

J Clin Med
Nolla JM, Benavent D, Valencia-Muntalà L, González-Aguila M, Alonso-Palao B, Gómez-Vaquero C, Narváez J, Juanola X, Berbel-Arcobé L.   +8 more
europepmc   +1 more source

Hematological Indices as Potential Biomarkers of Disease Activity in Ankylosing Spondylitis: LASSO-Based Multivariable Modelling. [PDF]

Medicina (Kaunas)
Kaymaz-Tahra S, Taşkın C, Tanoglu A.
europepmc   +1 more source

Exercise adherence, perceived exercise benefits and barriers, and spinal mobility in ankylosing spondylitis: a cross-sectional study. [PDF]

Rheumatol Int
Usen A, Kuculmez O, Yavuz MO.
europepmc   +1 more source

Effect of secukinumab dose escalation on MRI-detected inflammation and structural damage in axial spondyloarthritis: a clinical, investigator-initiated, treat-to-target study (TRACE). [PDF]

RMD Open
Vladimirova N, Østergaard M, Seven S, Møller JM, Jensen B, Østgård R, Poggenborg R, Madsen OR, Hendricks O, Brix L, Georgiadis S, Pedersen SJ.   +11 more
europepmc   +1 more source

The value of EQ-5D-3L and EQ VAS as a patient-reported outcome measure for patients with ankylosing spondylitis in routine healthcare: an evaluation of construct validity and responsiveness based on the Swedish Rheumatology Quality Register. [PDF]

J Patient Rep Outcomes
Degerlund-Maldi K, Regardt M, Nystrand Länsman C, Larsson L, Parodis I, Heintz E.   +5 more
europepmc   +1 more source

Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis. [PDF]

RMD Open
Maksymowych WP, Yeshokumar A, Cerullo E, Lambert RGW, Śliwinska-Stańczyk P, Klimiuk P, Kepich R, Pachai C, Zhu M, Liu J, Landis J, Goti V, Greenberg S.   +12 more
europepmc   +1 more source

Clinical efficacy of tofacitinib in active ankylosing spondylitis and dynamic changes in gut microbiota: an exploratory descriptive four-case series with 16S rRNA sequencing analysis. [PDF]

Front Immunol
Wang L, Xie W, Li J, Chen J, Huang Y.
europepmc   +1 more source